GS1 US® Publishes Guideline Update: Applying the GS1 System of Standards for U.S. FDA Unique Device Identification

Healionics Raises $4.7M Equity Round to Support Commercialization of STARgraft Vascular Graft

Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure.

St. Elizabeth Healthcare Enhances Access To Cardiac Care With Multi-specialty Outpatient Building

"We opened the Heart & Vascular Institute six years ago with the goal of improving access to quality cardiovascular care for individuals in our region, and since then, we've made impressive strides in service offerings and patient outcomes," said D.P. Suresh, MD, Cardiologist and Executive Medical Director of the St. Elizabeth HVI.

Burgeoning Demand for MRI-guided Radiation Therapy Systems Market to Fuel Market Growth Thorough the COVID-19 Crisis Period

The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by Fact.MR.

GS1 US® has published a significant update to its Implementation Guideline, “Applying the GS1 System of Standards for U.S. FDA Unique Device Identification (UDI),”which provides industry best practices for implementing GS1 identification and barcode standards on medical devices within the context of the U.S. Food and Drug Administration’s (FDA’s) UDI Rule. The updated version (R2.0) now reflects new language and context of the regulation since the first Implementation Guideline was published in 2014.

Since passing the U.S. FDA UDI Rule in 2013, the U.S. FDA has issued numerous updates and clarifications to help medical device manufacturers understand how to meet the requirements. These include U.S. FDA Draft Guidance, Final Guidance and extensions or modifications to certain aspects of the rule, such as direct marking of devices, enforcement policy on National Health Related Item Code (NHRIC) or National Drug Code (NDC) numbers assigned to devices and form and content of the unique device identifier, among others.

Accordingly, the updated Implementation Guideline developed by GS1 Healthcare US® – an industry group focused on helping improve patient safety and supply chain efficiency through the adoption of GS1 Standards – includes instructions for using GS1 Standards to assist in meeting some requirements of the U.S. FDA UDI Rule, including:

  • Device Identifier – GS1 Global Trade Item Number® (GTIN®)
  • Production Identifiers (PIs) – GS1 Application Identifiers (AIs)
  • Representation of UDI in GS1 barcodes and human readable plain text format
  • Direct marking UDI on devices – GS1 rules for permanently marked items
  • Global Unique Device Identification Database (GUDID) submission – GS1 Global Data Synchronization Network™ (GDSN®)

“The U.S. FDA UDI Rule establishes important standards for medical device identification that will bring about continuous improvements in the healthcare supply chain and ultimately help increase patient safety,” said Angela Fernandez, vice president of community engagement, GS1 US. “Companies that are just getting started with their UDI implementation program will find this guideline to be an invaluable resource for informing their process, and companies that already have UDI programs underway will benefit from the updated guidance covering all of the developments and changes that have occurred since the rule was first enacted.”

GS1 is a U.S. FDA-Accredited Issuing Agency for UDI, and GS1 Standards are authorized for use in implementing the requirements of the U.S. FDA UDI Rule.

To download the “Applying the GS1 System of Standards for U.S. FDA Unique Device Identification (UDI)” Guideline, visit here.



Subscribe to Medical Device News Magazine here.

Related Articles